Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 10-Q Quarterly Report
Corvus Pharmaceuticals, Inc. (CRVS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Corvus Pharmaceuticals, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: EU Clinical Trials Regulation fully effective Jan 31, 2025; centralized trial approvals via EU portal may impact development plans
- • Updated risk: Cash $65.7M insufficient to fund operations beyond 12 months from 10-Q date; risk of delays or termination of clinical trials without new financing
Get deeper insights on Corvus Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.